Trials / Terminated
TerminatedNCT00498914
Study of YM155 in Refractory Diffuse Large B-cell Lymphoma (DLBCL) Subjects
A Phase II Multicenter, Open-Label Study of YM155 in Refractory Diffuse Large B-Cell Lymphoma (DLBCL) Subjects
- Status
- Terminated
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 41 (actual)
- Sponsor
- Astellas Pharma Inc · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
A study in subjects with a type of B cell lymphoma (DLBCL)to evaluate the response rate, efficacy, safety and tolerability of YM155
Detailed description
1 arm (Active), Phase 2 Study to evaluate response rate, efficacy, safety and tolerability of YM155
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | YM155 | Continuous IV infusion |
Timeline
- Start date
- 2007-06-01
- Primary completion
- 2009-04-01
- Completion
- 2009-04-01
- First posted
- 2007-07-11
- Last updated
- 2015-09-04
Locations
22 sites across 4 countries: United States, Canada, France, Spain
Source: ClinicalTrials.gov record NCT00498914. Inclusion in this directory is not an endorsement.